| Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplex DR Calabrese, X Chen, EC Leon, SM Gaikwad, Z Phyo, WM Hewitt, ... Nature communications 9 (1), 4229, 2018 | 157 | 2018 |
| Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in … JV Alessi, B Ricciuti, SL Alden, AA Bertram, JJ Lin, M Sakhi, M Nishino, ... Journal for Immunotherapy of Cancer 9 (11), 2021 | 79 | 2021 |
| Progressive proximal-to-distal reduction in expression of the tight junction complex in colonic epithelium of virally-suppressed HIV+ individuals CY Chung, SL Alden, NT Funderburg, P Fu, AD Levine PLoS pathogens 10 (6), e1004198, 2014 | 77 | 2014 |
| A Compact Structure of Cytochrome c Trapped in a Lysine-Ligated State: Loop Refolding and Functional Implications of a Conformational Switch JF Amacher, F Zhong, GP Lisi, MQ Zhu, SL Alden, KR Hoke, DR Madden, ... Journal of the American Chemical Society 137 (26), 8435-8449, 2015 | 63 | 2015 |
| Characterization of clinically used oral antiseptics as quadruplex-binding ligands DR Calabrese, K Zlotkowski, S Alden, WM Hewitt, CM Connelly, ... Nucleic acids research 46 (6), 2722-2732, 2018 | 29 | 2018 |
| Probing the hras-1 Y i-motif with small molecules SN Journey, SL Alden, WM Hewitt, ML Peach, MC Nicklaus, ... Medchemcomm 9 (12), 2000-2007, 2018 | 16 | 2018 |
| Salvage ipilimumab plus nivolumab after anti-PD-1/PD-L1 therapy in advanced hepatocellular carcinoma SL Alden, M Lim, C Kao, D Shu, AG Singal, A Noonan, P Griffith, M Baretti, ... Cancer Research Communications 3 (7), 1312-1317, 2023 | 13 | 2023 |
| The K79G Mutation Reshapes the Heme Crevice and Alters Redox Properties of Cytochrome c Y Deng, F Zhong, SL Alden, KR Hoke, EV Pletneva Biochemistry 57 (40), 5827-5840, 2018 | 13 | 2018 |
| Prediction of outcomes with a computational biology model in newly diagnosed glioblastoma patients treated with radiation therapy and temozolomide R Rahman, L Trippa, S Alden, G Fell, T Abbasi, Y Mundkur, NK Singh, ... International Journal of Radiation Oncology* Biology* Physics 108 (3), 716-724, 2020 | 10 | 2020 |
| Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer A Di Federico, SL Alden, JW Smithy, B Ricciuti, JV Alessi, X Wang, ... Annals of Oncology 35 (10), 902-913, 2024 | 5 | 2024 |
| Circulating tumor DNA to predict radiographic and pathologic response to total neoadjuvant therapy in locally advanced rectal cancer SL Alden, V Lee, AK Narang, J Meyer, SL Gearhart, ES Christenson The Oncologist 29 (3), e414-e418, 2024 | 4 | 2024 |
| 312 Three-year outcomes with first-line pembrolizumab for metastatic non–small-cell lung cancer (NSCLC) with a very high PD-L1 tumor proportion score (TPS)≥ 90% B Ricciuti, JV Alessi, S Alden, G Lamberti, V Vaz, A Barrichello, L Sholl, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | 4 | 2021 |
| Comparing Properties of Common Bioinorganic Ligands with Switchable Variants of Cytochrome c F Zhong, SL Alden, RP Hughes, EV Pletneva Inorganic Chemistry 61 (3), 1207-1227, 2021 | 4 | 2021 |
| Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures CJ Kao, S Charmsaz, SL Alden, M Brancati, HL Li, A Balaji, K Munjal, ... The Journal of Clinical Investigation 134 (20), 2024 | 3 | 2024 |
| Salvage ipilimumab plus nivolumab in advanced hepatocellular carcinoma after prior anti-PD-(L) 1 blockade. SL Alden, M Lim, C Kao, D Shu, AG Singal, AM Noonan, P Griffith, ... Journal of Clinical Oncology 41 (16_suppl), 4091-4091, 2023 | 3 | 2023 |
| BRAF-Mutant Pulmonary Langerhans Cell Histiocytosis Mimicking Recurrence of Early-Stage KRAS-Mutant Lung Adenocarcinoma SL Alden, SJ Swanson, M Nishino, LM Sholl, MM Awad JTO Clinical and Research Reports 2 (2), 2021 | 3 | 2021 |
| Incidence, risk factors, and outcomes of immune-related adverse events (irAEs) in a prospective, pan-tumor population. A Balaji, SL Alden, H Li, K Munjal, EJ Lipson, J Naidoo, L Cappelli, Y Ged, ... Journal of Clinical Oncology 41 (16_suppl), 2662-2662, 2023 | 2 | 2023 |
| Post-operative ctDNA monitoring in stage I colon cancer: a case report SL Alden, H Dhani, C Palsuledesai, S Krinshpun, A Jurdi, E Christenson, ... Frontiers in Oncology, 7044, 2022 | 1 | 2022 |
| P14. 21 Baseline Derived Neutrophil-to-Lymphocyte Ratio (dNLR) and Clinical Outcomes to First-Line Pembrolizumab in NSCLC with High PD-L1 (≥ 50%) JV Alessi, B Ricciuti, S Alden, M Awad Journal of Thoracic Oncology 16 (3), S338-S339, 2021 | 1 | 2021 |
| P33. 04 programmed death-ligand 1 (PD-L1) changes in non-small-cell lung cancer (NSCLC): Clinical, pathologic, and genomic correlates S Alden, B Ricciuti, L Spurr, H Gupta, G Lamberti, Y Li, L Sholl, ... Journal of Thoracic Oncology 16 (3), S406-S407, 2021 | 1 | 2021 |
